OrthoLogic Chrysalin Phase III Fracture Repair NDA Study To Begin This Fall
This article was originally published in The Gray Sheet
Executive Summary
OrthoLogic believes that pursuing approval of its orthobiologic product Chrysalin through a new drug application (NDA) will enable fuller discussion of the product's method of action in marketing materials